By Sabela Ojea
Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its pandemic influenza shots.
The financial package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the biotechnology company said Friday.
The agreement will also fund the expansion of clinical studies for up to five additional subtypes of pandemic influenza, Moderna added.
The financial support from the federal government comes right before President-elect Donald Trump takes office on Monday, and at a time when Moderna is preparing to advance its mRNA-1018 investigational pandemic influenza vaccine into a Phase 3 trial.
In 2023, Moderna initiated a phase 1/2 study to generate safety and immunogenicity data of the shot in healthy adults ages 18 and older. The trial included vaccine candidates against two avian influenza viruses, H5 and H7.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 17, 2025 16:29 ET (21:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。